243 related articles for article (PubMed ID: 17457342)
1. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.
Riedemann L; Lanvers C; Deuster D; Peters U; Boos J; Jürgens H; am Zehnhoff-Dinnesen A
Pharmacogenomics J; 2008 Feb; 8(1):23-8. PubMed ID: 17457342
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms.
Choeyprasert W; Sawangpanich R; Lertsukprasert K; Udomsubpayakul U; Songdej D; Unurathapan U; Pakakasama S; Hongeng S
J Pediatr Hematol Oncol; 2013 May; 35(4):e138-43. PubMed ID: 23274376
[TBL] [Abstract][Full Text] [Related]
3. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
4. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected.
Schmidt CM; Knief A; Lagosch AK; Deuster D; am Zehnhoff-Dinnesen A
Ear Hear; 2008 Dec; 29(6):830-7. PubMed ID: 18772725
[TBL] [Abstract][Full Text] [Related]
5. [Ototoxicity of cisplatin in children with malignant diseases].
Hadjilaskari P; Fengler R; Hartmann R; Henze G
Klin Padiatr; 1989; 201(4):316-21. PubMed ID: 2779137
[TBL] [Abstract][Full Text] [Related]
6. Sequence variations of mitochondrial DNA and individual sensitivity to the ototoxic effect of cisplatin.
Peters U; Preisler-Adams S; Lanvers-Kaminsky C; Jürgens H; Lamprecht-Dinnesen A
Anticancer Res; 2003; 23(2B):1249-55. PubMed ID: 12820379
[TBL] [Abstract][Full Text] [Related]
7. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.
Li Y; Womer RB; Silber JH
Eur J Cancer; 2004 Nov; 40(16):2445-51. PubMed ID: 15519518
[TBL] [Abstract][Full Text] [Related]
8. [Early detection of cisplatin-induced ototoxicity using evoked otoacoustic emissions].
Plinkert PK; Kröber S
Laryngorhinootologie; 1991 Sep; 70(9):457-62. PubMed ID: 1930486
[TBL] [Abstract][Full Text] [Related]
9. [The ototoxicity of cisplatin: a clinical study].
Vantrappen G; Rector E; Debruyne F
Acta Otorhinolaryngol Belg; 1990; 44(4):415-21. PubMed ID: 2093285
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
11. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
Knight KR; Kraemer DF; Winter C; Neuwelt EA
J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008
[TBL] [Abstract][Full Text] [Related]
12. [Genetic background of cisplatin induced ototoxicity].
Jurajda M; Talach T; Kostřica R; Lakomý R; Kocák I; Cvanová M
Klin Onkol; 2012; 25(3):184-7. PubMed ID: 22724567
[TBL] [Abstract][Full Text] [Related]
13. [Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention].
Montaguti M; Brandolini C; Ferri GG; Hatzopoulos S; Prete A; Pession A
Acta Otorhinolaryngol Ital; 2002 Feb; 22(1):14-8. PubMed ID: 12236007
[TBL] [Abstract][Full Text] [Related]
14. Ototoxicity in children treated for osteosarcoma.
Lewis MJ; DuBois SG; Fligor B; Li X; Goorin A; Grier HE
Pediatr Blood Cancer; 2009 Mar; 52(3):387-91. PubMed ID: 19061216
[TBL] [Abstract][Full Text] [Related]
15. cis-platinum ototoxicity in children.
Pasic TR; Dobie RA
Laryngoscope; 1991 Sep; 101(9):985-91. PubMed ID: 1886448
[TBL] [Abstract][Full Text] [Related]
16. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma.
Kushner BH; Budnick A; Kramer K; Modak S; Cheung NK
Cancer; 2006 Jul; 107(2):417-22. PubMed ID: 16779793
[TBL] [Abstract][Full Text] [Related]
17. [Cisplatin ototoxicity. A clinical study].
Schröder M; Laskawi R; Stennert E; Kühnle H; Thiele FW
Laryngol Rhinol Otol (Stuttg); 1986 Feb; 65(2):86-9. PubMed ID: 3959692
[TBL] [Abstract][Full Text] [Related]
18. [Monitoring hearing during ototoxic cisplatin therapy].
Kluba J; Kluba U; von Specht H; Mittler U
Padiatr Grenzgeb; 1990; 29(1):19-23. PubMed ID: 2342815
[TBL] [Abstract][Full Text] [Related]
19. High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity.
Thomas JP; Lautermann J; Liedert B; Seiler F; Thomale J
Mol Pharmacol; 2006 Jul; 70(1):23-9. PubMed ID: 16569706
[TBL] [Abstract][Full Text] [Related]
20. Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma.
Lafay-Cousin L; Purdy E; Huang A; Cushing SL; Papaioannou V; Nettel-Aguirre A; Bouffet E
Pediatr Blood Cancer; 2013 Feb; 60(2):287-92. PubMed ID: 23002030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
